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latter considered to be a “true” treatment failure. 
Our main hypothesis was that the four treat-
ments would have similar efficacy, and indeed 
the differences between the PCR-adjusted cure 
rates were within the prespecified equivalence 
margin of 5 percentage points. Genotyping was 
carried out according to standard methods,1 
whose limitations, particularly where transmis-
sion is intense, were mentioned in the Discussion 
section of our article. Adekunle et al. state that 
the recrudescence rate equates to resistance. 
However, it is well known that this is not true, 
because observed therapeutic failure may be due 
to factors other than parasitologic resistance 
(e.g., malabsorption and rapid or abnormal me-
tabolism),2 and this may be particularly true for 
pregnant women.3 We have also stated that there 
are major differences in the duration of the post-
treatment prophylaxis between treatments, and 
this is shown by the PCR-unadjusted cure rates.
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Trimethoprim–Sulfamethoxazole for Uncomplicated  
Skin Abscess
To the Editor: Talan et al. (March 3 issue)1 
slightly misstate the findings of an earlier sum-
mary to which I contributed.2 My fellow authors 
and I concluded that prior studies of antibiotics 
administered in patients with uncomplicated ab-
scesses were underpowered because the authors 
of those studies could not rule out the 5 to 10% 
superiority of antibiotics suggested in our review. 
The current study was well designed to address 
this concern. Comment is also warranted regard-
ing the trial guidance provided by the Food and 
Drug Administration (FDA) on an early end point 
that is required as the primary end point for reg-
istrational studies and was a secondary end point 
in the study by Talan et al. The FDA guidance 
indicates that patients are considered to have 
been treated successfully even if 80% of their in-
fection remains unresolved after 3 days of thera-
py. Space limitations here preclude a thorough 
discussion of this objectionable end point.3 The 
trial by Talan et al. is at least the second random-
ized, controlled trial (RCT) that has shown that 
the early end point does not correlate well with 
test-of-cure success.4 Furthermore, the current 
trial adds to the data that show that an “end-of-
therapy cure” end point is sensitive to the effi-
cacy of the antibiotic for skin infections.5 In my 
opinion, the early end point should be aban-
doned.
Brad Spellberg, M.D.
LAC+USC Medical Center 
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To the Editor: Talan et al. reported higher per-
protocol cure rates for abscesses treated with tri-
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methoprim–sulfamethoxazole in addition to in-
cision and drainage than for abscesses treated 
with incision and drainage alone (92.9% vs. 
85.7%). However, the dimensions of the abscess-
es varied greatly, ranging from a few millimeters 
up to 16 cm in their largest measure, and the 
dimensions of associated erythema ranged from 
1 to 49 cm. Stratifying the success rates for inci-
sion and drainage according to lesion size could 
help clinicians determine when antibiotics may 
not be useful. In addition, it would be interesting 
to know the location of the erythema with re-
spect to the abscess (e.g., a patch of cellulitis ex-
tending entirely proximal to the abscess may be 
more likely to warrant antibiotic coverage than a 
patch that shows concentric extension). Guide-
lines from the Infectious Diseases Society of 
America note that “For simple abscesses or boils, 
incision and drainage alone is likely to be ade-
quate, but additional data are needed to further 
define the role of antibiotics, if any, in this set-
ting.”1 It would be unfortunate if clinicians were 
to interpret the findings of Talan et al. as imply-
ing that antibiotics should now be routinely pre-
scribed.
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To the Editor: The study by Talan et al. sup-
ports the use of antibiotics as an adjunctive treat-
ment for uncomplicated skin abscesses, but this 
recommendation runs contrary to current efforts 
to reduce antibiotic use in the face of the rising 
threat of antimicrobial resistance.1,2 We note that 
up to a quarter of the swabs processsed in the 
study showed either no growth or coagulase-
negative staphylococcal growth. Did the authors 
find a difference in response rate stratified ac-
cording to these culture results? In addition, 
since high adherence to antibiotic therapy was 
achieved in only 64.7% of study participants, was 
a subanalysis performed for those who received 
courses that were shorter than prescribed? When 
antibiotics are used as an adjunct to drainage, 
the majority of bacteria are probably removed 
during surgery, and recent studies have shown 
that adequate source control can shorten the 
standard course of antibiotics without reducing 
clinical efficacy.3 Therefore, it is likely that when 
antibiotics are used as an adjunctive treatment, a 
shorter course would provide equivalent clinical 
benefit and would also reduce the risks of ad-
verse effects, limit total antibiotic consumption, 
and decrease the selective pressure toward the 
development of resistance.
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The authors reply: Spellberg emphasizes that 
in our study, unlike previous RCTs, we powered 
our superiority trial to detect a difference of 5 to 
10 percentage points in primary outcome.1 Our 
primary outcome was clinical cure of the abscess 
such that no new antibiotic was indicated ac-
cording to standardized criteria. We evaluated 
cure between 7 and 14 days after treatment, a 
period of time that was consistent with FDA in-
dustry guidance until 2010. Subsequently, the 
FDA recommended the use of early response as 
the primary outcome — that is, there should be 
no increase in lesion size within 48 to 72 hours 
after treatment.2 The FDA then revised this crite-
rion, recommending a decrease in lesion size of 
20%. We developed our protocol before this 
guidance was available. Considering the persis-
tent and recurrent nature of some abscesses, we 
believed that differences in clinical care would 
probably be detected later. We also evaluated 
rates of new infections and additional surgical 
procedures.
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As Spellberg indicates, whereas we found no 
significant between-group difference in early 
response rates, at 7 to 14 days after treatment, 
the participants who received treatment with 
trimethoprim–sulfamethoxazole had an abscess 
cure rate that was significantly higher (by 7 per-
centage points) than that of participants treated 
with placebo. At 6 to 8 weeks after treatment, 
these participants had significantly lower rates 
of new infections and drainage procedures. An 
alternative primary outcome, composite clinical 
cure, was lesion resolution without the addition 
of a new antibiotic or further drainage; the use 
of trimethoprim–sulfamethoxazole was also fa-
vored for this measure, by 12 percentage points. 
Our results elucidate the history of treated skin 
abscesses and challenge current FDA guidance, 
particularly the guidance for noninferiority reg-
istration trials.
Leiner has concerns about the use of antibiot-
ics becoming routine, and Pollara and Marks 
raise stewardship questions. Our findings are 
appropriately applied only to patients similar to 
our trial participants (i.e., those who have an 
abscess measuring at least 2 cm in diameter and 
whose clinician intends outpatient treatment). In 
our study, most abscesses measured 2 to 3 cm in 
diameter (with a median erythema length of 7 
cm), but some were much larger. We agree that 
subgroup analyses of conditions for which there 
is a theoretical association with a greater antibi-
otic effect, such as larger size, could be informa-
tive. We will see whether another multicenter 
RCT (ClinicalTrials.gov. number NCT00730028) 
in which antibiotics are compared with placebo 
supports our findings and hope to validate sub-
group treatment associations to further inform 
decision making. However, we have shown that 
trimethoprim–sulfamethoxazole (which typical-
ly has a cost of less than $5 per course) leads to 
superior outcomes and is generally safe, which 
justifies discussion of this option with patients 
at the least. The risk of promotion of bacterial 
resistance is probably small with our regimen, 
since it involves the use of high-dose trime-
thoprim–sulfamethoxazole (320 mg and 1600 mg, 
respectively, twice daily) for 7 days in healthy, 
community-dwelling patients with an identifi-
able bacterial infection. We do not know wheth-
er a shorter regimen would be efficacious. The 
fact that some lesions were culture-negative or 
grew coagulase-negative staphylococci is proba-
bly due to the limitations of culture technique 
and not the presence of a nonbacterial cause of 
infection.
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Kidney Transplants from HLA-Incompatible Live Donors  
and Survival
To the Editor: Orandi et al. (March 10 issue)1 
report a survival benefit among patients who 
received a kidney transplant from an HLA- 
incompatible live donor, as compared with 
those who did not undergo transplantation and 
those who waited for a transplant from a de-
ceased donor. However, three variables could 
distinguish patients who underwent desensiti-
zation before HLA-incompatible transplantation 
from those in the two other study groups, de-
spite the efforts that were made to find the most 
effective matches.
First, patients receiving an HLA-incompatible 
live-donor transplant appeared to have higher 
survival rates as early as 0.02 months (0.6 days) 
after transplantation. Such immediate differ-
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